A scientific breakthrough may lead to the development of a new range of drugs against cancer, British researchers report today.
The scientists say they have unlocked the secret of why several cancer drugs work.
The findings are being unveiled at the National Cancer Research Institute conference in Birmingham today – and also published in the journal Embo Reports.
The research has identified a process dubbed NEDDylation – which hampers a gene called p53, that would normally prevent the replication of cancer cells.
At the centre of it is a molecule called NEDD8, which alters the properties of some proteins, preventing them moving and triggering the activation of p53.
Researcher Dr Dimitris Xirodimas, of Dundee University, Scotland, said chemicals which block the reaction had recently been developed by a pharmaceutical company.
He said: "These compounds are currently being tested in clinical trials for the treatment of cancer.
"Our research reinforces the value of this work and opens up avenues for the development of new ways to treat cancer."
Dr Mark Matfield, scientific adviser to Cancer Research UK, said: "The significance of this discovery is that it could lead to drugs that would be effective against a wide range of cancers. Over the last decade, many of the new cancer drugs have only been useful for a few, specific cancers. What we really need are effective broad range cancer therapies."
And Professor Sir David Lane, its chief scientist, said: "p53 is missing or faulty in almost half of all cancers and there are 270,000 new cases of cancer in the UK each year so by understanding potential therapies can switch it on and off is an important part of the search for new potential therapies."
Regulation of nucleolar signalling to p53 through NEDDylation of L11. Anders Sundqvist et al. EMBO Reports

Leave a Reply